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Abstract
Background: Aurora kinases and loss of p53 function are implicated in the carcinogenesis of aneuploid
esophageal cancers. Their association with occurrence of multipolar mitoses in the two main histotypes of
aneuploid esophageal squamous cell carcinoma (ESCC) and Barrett’s adenocarcinoma (BAC) remains unclear. Here,
we investigated the occurrence of multipolar mitoses, Aurora-A/-B gene copy numbers and expression/activation
as well as p53 alterations in aneuploid ESCC and BAC cancer cell lines.
Results: A control esophageal epithelial cell line (EPC-hTERT) had normal Aurora-A and -B gene copy numbers and
expression, was p53 wild type and displayed bipolar mitoses. In contrast, both ESCC (OE21, Kyse-410) and BAC
(OE33, OE19) cell lines were aneuploid and displayed elevated gene copy numbers of Aurora-A (chromosome 20
polysomy: OE21, OE33, OE19; gene amplification: Kyse-410) and Aurora-B (chromosome 17 polysomy: OE21, Kyse-
410). Aurora-B gene copy numbers were not elevated in OE19 and OE33 cells despite chromosome 17 polysomy.
Aurora-A expression and activity (Aurora-A/phosphoT288) was not directly linked to gene copy numbers and was
highest in Kyse-410 and OE33 cells. Aurora-B expression and activity (Aurora-B/phosphoT232) was higher in OE21
and Kyse-410 than in OE33 and OE19 cells. The mitotic index was highest in OE21, followed by OE33 > OE19 >
Kyse-410 and EPC-hTERT cells. Multipolar mitoses occurred with high frequency in OE33 (13.8 ± 4.2%), followed by
OE21 (7.7 ± 5.0%) and Kyse-410 (6.3 ± 2.0%) cells. Single multipolar mitoses occurred in OE19 (1.0 ± 1.0%) cells.
Distinct p53 mutations and p53 protein expression patterns were found in all esophageal cancer cell lines, but
complete functional p53 inactivation occurred in OE21 and OE33 only.
Conclusions: High Aurora-A expression alone is not associated with overt multipolar mitoses in aneuploid ESCC
and BAC cancer cells, as specifically shown here for OE21 and OE33 cells, respectively. Additional p53 loss of
function mutations are necessary for this to occur, at least for invasive esophageal cancer cells. Further assessment
of Aurora kinases and p53 interactions in cells or tissue specimens derived from non-invasive dysplasia (ESCC) or
intestinal metaplasia (BAC) are necessary to disclose a potential causative role of Aurora kinases and p53 for
development of aneuploid, invasive esophageal cancers.
Background
Esophageal cancer is one of the leading causes of death
from cancers worldwide. The two major histotypes of
esophageal cancer are esophageal squamous cell carci-
noma (ESCC) and Barrett’s adenocarcinoma (BAC) [1,2].
Several specific molecular alterations play crucial roles
in the carcinogenesis of ESCC or BAC, with tumor cell
aneuploidy and p53 mutations being major hallmarks of
both ESCC and BAC [3-5]. In fact, aneuploidy is found
in 50% to 70% of ESCC and is associated with poor
prognosis [6,7]. In BAC, similar high rates of aneuploidy
are seen for invasive carcinomas [8,9], and aneuploidy is
an early event in the metaplasia-dysplasia-adenocarci-
noma sequence of BAC. Moreover, p53 is mutated in
35% to 80% of ESCC and in about 50% to 90% of BAC
[4,10,11].
Together with deregulation of mitotic and post-mito-
tic cell cycle control points, the presence of supernu-
merary centrosomes has been proposed as one likely
* Correspondence: silke.lassmann@uniklinik-freiburg.de
1Institute of Pathology, University Medical Center, Freiburg, Germany
Full list of author information is available at the end of the article
Fichter et al. BMC Cell Biology 2011, 12:13
http://www.biomedcentral.com/1471-2121/12/13
© 2011 Fichter et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.mechanism for development and/or maintenance of
aneuploidy [12]. Supernumerary centrosomes have been
detected in several aneuploid human cancers or cell
lines derived thereof by evaluation of centrosomal pro-
teins, such as g-tubulin, pericentrin or Inhibitor of DNA
binding protein 1 (ID1) [13-15]. However, the associa-
tion of supernumerary centrosomes with multipolar
mitoses in aneuploid ESCC and BAC cells has not been
studied so far.
T h eA u r o r ak i n a s ef a m i l yo fs e r i n e / t h r e o n i n ek i n a s e s
regulates many processes during cell division and is cur-
rently discussed as therapeutic target in cancer [16,17].
Specifically, Aurora-A is important for centrosome
maturation, separation and spindle assembly [16].
Amplification of the Aurora-A locus (AURKA, 20q13.2)
and subsequent overexpression of Aurora-A was
observed for example in colorectal [18] and pancreatic
cancer [19], as well as in ESCCs and BACs [20-26].
Overexpression of Aurora-A has been functionally asso-
ciated with supernumerary centrosomes and aneuploidy
[27-31]. In esophageal cancers, a polymorphism of Aur-
ora-A was associated with increased esophageal cancer
risk. This Aurora-A polymorphism showed reduced
Aurora-A kinase activity, lack of phosphorylation of its
substrate Lats2 and associated genetic instability, at least
by ectopic expression of the Aurora-A isoforms in
immortalized fibroblasts [32]. Whether or not lack of
Lats2 phosphorylation alone and/or other alterations of
the Aurora-A isoforms, such as incorrect intracellular
localization, are responsible for genomic instability in
esophageal cancer cells remained elusive.
In contrast, Aurora-B is involved in kinetochore-
microtubule interactions, chromosome condensation
and cytokinesis [16]. Together with INCENP, survivin
and borealin, Aurora-B builds the chromosomal passen-
ger complex [33]. The Aurora-B gene (AURKB)i s
located in the chromosomal region 17p13.1 [16], which
is also frequently altered in ESCCs and BACs [34-37].
Although the role of Aurora-B in human cancer is less
clear than for Aurora-A, an association between Aurora-
B overexpression and aneuploidy has been reported for
some cancer cell lines [16,38]. However, in esophageal
cancer the association of Aurora-A and Aurora-B with
occurrence of multipolar mitoses in aneuploid ESCC or
BAC cells remains elusive so far.
In view of the crucial role of the tumor suppressor
p53 for maintenance of genetic stability [39,40] and its
frequent mutation in esophageal cancer [4,10,11], it is of
interest that also a centrosomal localization and func-
tional involvement in centrosome duplication has been
described for p53 [41-43]. Moreover, p53 can be phos-
phorylated by Aurora-A, leading to MDM2 dependent
p53 inactivation and degradation and/or loss of p53
transactivation activity [44,45]. Together, (Aurora-A
dependent or independent) disruption of p53 function
may result in escape of the p53 dependent G1 post-
mitotic checkpoint [46] and potentially also centrosomal
dysfunction.
The aim of the present study was to investigate the
occurrence of multipolar mitoses and association with
Aurora kinases and p53 mutations in previously estab-
lished esophageal carcinoma cell lines [47-49] and con-
trol esophageal epithelial cells [50-52].
Results
Ploidy and cell cycle distribution in normal esophageal
epithelial cells and esophageal cancer cells
For the present study, a control diploid cell line derived
from normal esophageal epithelial cells [50,51] as well
as four aneuploid esophageal cancer cell lines with squa-
mous cell (OE21, Kyse-410, hereafter referred to as
ESCC) and adenocarcinoma (OE33, OE19, hereafter
referred to as “BAC”) differentiation and growth pat-
terns [47-49,52], i.e. closely reflecting the morphological
features of the two main histotypes of esophageal can-
cer, were used. All experimental data shown are derived
from each three independent experiments.
Ploidy, respective DNA content, as well as cell cycle
distribution patterns of all five cell lines was first defined
by flow cytometry. This validated diploidy of EPC-
hTERT cells and aneuploidy to different levels in the
esophageal cancer cell lines (Figure 1A). To further
define chromosome numbers in the aneuploid esopha-
geal cancer cell lines, each 10 metaphase spreads were
analyzed and revealed highest chromosome numbers in
OE33 (100.2 ± 4.4), followed by Kyse-410 (89.6 ± 5.1),
OE21 (70.6 ± 2.5) and OE19 (56.8 ± 1.8) cells. Analyses
of cell cycle distribution (Figure 1B) revealed that ESCC
cells (OE21, Kyse-410) showed similarly distributed cell
populations in G0/G1-, S- and G2/M-phases (each
about 20-30%). In contrast, OE33 (~30%) and markedly
OE19 (~50%) and EPC-hTERT (~70%) cells had a high
G0/G1-phase population, with reduced S- and G2/M-
phase populations.
Aurora kinases in normal esophageal epithelial cells and
esophageal cancer cells
For Aurora-A (Table 1, Figure 2), fluorescence in situ
hybridization (FISH) revealed chromosome 20 polysomy
with concomitantly elevated Aurora-A gene copy num-
bers in OE21, OE33 and OE19 cells and an Aurora-A
gene amplification with up to nine Aurora-A gene
copies in Kyse-410 cells. In view of their Aurora-A gene
amplification, Kyse-410 cells also showed highest Aur-
ora-A mRNA (qRT-PCR) and high protein (immuno-
blot) expression. In contrast, OE21, OE33 and OE19
cells exhibited lower Aurora-A mRNA expression,
despite chromosome 20 polysomy. Still, high Aurora-A
Fichter et al. BMC Cell Biology 2011, 12:13
http://www.biomedcentral.com/1471-2121/12/13
Page 2 of 16protein expression was seen in OE33, but not OE21 and
OE19 cells. Active (phosporylated T288) Aurora-A was
hardly detectable in immunoblot analysis, but weak Aur-
ora-A/phosphoT288 levels were seen in OE21, Kyse-410
and OE33 cells. Control EPC-hTERT cells had normal
diploid Aurora-A gene copy numbers, lowest Aurora-A
mRNA expression, but detectable strong Aurora-A and
weak Aurora-A/phosphoT288 protein levels.
For Aurora-B (Table 1, Figure 3), chromosome 17
polysomy and concomitantly elevated Aurora-B gene
copy numbers were observed by FISH in the ESCC cell
lines OE21 and Kyse-410. Interestingly, in the BAC cell
Figure 1 Cell cycle phase distribution analysis by flow cytometry in normal esophageal epithelial cells and esophageal cancer cells. A.
The histograms show the cell cycle phase distribution, representative for 3 independent experiments. Note the increasing PI-staining/DNA
content from EPC-hTERT cells to OE21, Kyse-410, OE33 and OE19 cells. Proliferating cells in red, apoptotic cells in green. B. The bar graph shows
the distribution of cells in G0/G1-, S- and G2/M-phase of the cell cycle (mean and ± standard deviation of three independent experiments).
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signals with lower Aurora-B gene specific signals, result-
ing in Aurora-B to chromosome 17 ratios below 1, were
observed. Accordingly, both ESCC (OE21, Kyse-410) cell
lines had slightly higher Aurora-B mRNA and protein
expression than the BAC cell lines (OE33, OE19). Active
(phosphorylated T232) Aurora-B was apparent in OE21,
Kyse-410 and OE33 cells. Control EPC-hTERT cells had
normal diploid Aurora-B gene copy numbers, similar
Aurora-B mRNA as BAC cell lines, but undetectable
Aurora-B protein expression or activity.
The low Aurora-B gene copy numbers and protein
expression in the two BAC cell lines were not due to a
general phenomenon of entire chromosome 17 altera-
tions, since (other than AURKB at 17p13) HER2 gene
copy numbers (17q21) were highly amplified in these
two cell lines (Supplementary figure 1).
Thus, Aurora-A and -B gene copy numbers are linked
to mRNA expression patterns, but this is not directly
translated into altered protein or activity levels. Whilst
high Aurora-A and Aurora-B protein levels largely
reflect DNA copy numbers as well as cell cycle distribu-
tion in some cell lines (OE21, Kyse-410), decoupling of
Aurora-A and/or -B gene copy numbers with expression
and cell cycle distribution occurs in other cell lines (par-
ticularly OE33).
High Aurora-A expression alone is not associated with
occurrence of multipolar mitoses in esophageal cancer cells
Aurora-A gene amplification and protein overexpression
have been linked to the occurrence of supernumerary
centrosomes, formation of multipolar mitoses and aneu-
ploidy [27,30]. We therefore next examined the occur-
rence of Aurora-A positive multipolar mitoses in the
EPC-hTERT as well as the four esophageal cancer cell
lines. For this, three independent experiments were per-
formed by quantitative, Aurora-A specific, indirect
immunofluorescence [30] with asynchronized cells, to
detect occurrence of mitoses and multipolar mitoses in
view of their own cell cycle dynamics (Table 2, Figure
4). Parallel hematoxylin and eosin (HE) staining con-
firmed the data on mitotic cells morphologically and
pericentrin-specific indirect immunofluorescence [14,30]
confirmed the presence of Aurora-A associated supernu-
merary centrosomes.
To specify the previous flow cytometric analyses (Fig-
ure 1), which only provided data on the total number of
G2/M-phase cells, the mitotic index (i.e. only mitotic
cells per total cells in %) was evaluated in indirect
immunofluorescence analysis of Aurora-A and nuclear
(DAPI) staining. For each cell line at least 100 cells were
counted in three independent experiments (total at least
300 cells for each cell line; Table 2A, Figure 4). This
revealed the highest mitotic index in OE21 (4.6 ± 1.2%),
followed by OE33 (3.4 ± 2.25%), OE19 (3.2 ± 1.9%),
Kyse-410 (2.2 ± 0.4%) and EPC-hTERT (1.0 ± 0.0%)
cells.
Similarly, the occurrence of multipolar mitoses (i.e.
multipolar mitoses per total mitoses in %) was assessed
by quantifying indirect immunofluorescence analysis of
Aurora-A and nuclear (DAPI) stainings. For this, in
each cell line at least 80 mitoses were counted in three
independent experiments (total at least 265 mitoses for
each cell line; Table 2B, Figure 4). Aurora-A positive
multipolar mitoses were most frequent in OE33 (13.8 ±
4.2%) followed by OE21 (7.7 ± 5.0%) and Kyse-410 (6.3
± 2.0%) cells. OE19 cells (1.0 ± 1.0%) as well as EPC-
hTERT cells (0.3 ± 0.6%), if any, only had single Aur-
ora-A positive multipolar mitoses. Presence of supernu-
merary centrosomes in these multipolar mitoses was
confirmed by pericentrin staining (Figure 4, right
panels).
These data suggest that similarly high Aurora-A
expression (as seen e.g. for Kyse-410 and OE33 cells)
alone is insufficient to induce prominent multipolar
mitoses in aneuploid esophageal cancer cells.
Table 1 Aurora-A and -B gene copy numbers in normal esophageal epithelial and esophageal cancer cell lines
ESCC BAC
EPC-hTERT OE21 Kyse-410 OE33 OE19
Aurora-A
Aurora-A gene copies 2.0 ± 0.2 4.2 ± 0.5 9.1 ± 1.2 7.5 ± 0.9 3.9 ± 0.3
Centromere 20 signals 1.9 ± 0.3 4.1 ± 0.7 4.6 ± 0.9 7.2 ± 0.9 2.9 ± 0.4
Aurora-A/CEP20 ratio 1.1 ± 0.3 1.1 ± 0.3 2.0 ± 0.4 1.1 ± 0.1 1.4 ± 0.2
Aurora-B
Aurora-B gene copies 1.9 ± 0.4 3.0 ± 0.1 3.7 ± 0.8 2.9 ± 0.7 2.0 ± 0.2
Centromere 17 signals 2.0 ± 0.2 3.0 ± 0.1 3.8 ± 0.7 4.9 ± 0.9 3.9 ± 0.4
Aurora-B/CEP17 ratio 1.0 ± 0.2 1.0 ± 0.0 1.0 ± 0.1 0.6 ± 0.2 0.5 ± 0.1
The table summarizes results of FISH analyses of control esophageal epithelial cells (EPC-hTERT) and all four esophageal cancer cell lines, with mean and ±
standard deviation of gene specific (Aurora-A, Aurora-B) and centromere (CEP, chromosome enumeration probe) specific FISH signals as well as the amplification
status (gene to centromere ratio: Aurora-A to CEP20; Aurora-B to CEP17).
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in esophageal cancer cells
In view of the role of p53 in post-mitotic cell cycle
control, centrosome duplication and Aurora-A interac-
tion [41-45,53] as well as its frequent mutation in eso-
phageal carcinogenesis [4,10,11], we next determined
p53 mutation status [54,55], p53 protein expression
and intracellular localization [39] in the control EPC-
hTERT cell line and in the four esophageal cancer cell
lines (Figure 5).
The control EPC-hTERT cells exhibited a wild type
p53 sequence and showed weak p53 protein expression
in immunoblot (Figure 5B) and indirect immunofluores-
cence analysis (Figure 5C). This wild type p53 protein
was located in the cytoplasm of EPC-hTERT cells.
In contrast, all ESCC and BAC cell lines displayed p53
mutations (Figure 5A): OE21 cells exhibited p53 muta-
tions in exon 4 (c.269C>T, c.270delC, p.S90fs31X),
which introduce a stop codon at the N-terminus of the
p 5 3c o r ed o m a i n .T h ep 5 3p r o t e i no fO E 2 1c e l l sl a c k s
almost the entire DNA binding domain, the tetrameriza-
tion domain and the extreme C-terminus (protein mass
of truncated protein is about 14 kDa). This protein, if at
all being expressed, is most likely non-functional since
almost all domains are missing, including the Aurora-A
interaction sites Serine 215 and 315. Indeed, immuno-
blot analysis did not detect this largely truncated p53
protein (Figure 5B) and immunofluorescence showed
only weak and rather diffusely localized p53 staining in
OE21 cells (Figure 5C).
Figure 2 Aurora-A gene copy numbers, mRNA and protein expression in normal esophageal epithelial cells and esophageal cancer
cells. A. FISH analysis of AURKA (red signals) and Chromosome 20 (CEP20; green signals). Bar = 20 μm, all panels are in the same magnification.
B. Relative Aurora-A mRNA expression was determined by qRT-PCR (mean ± standard deviation of three independent experiments). C.
Photograph of Aurora-A/phospho-T288 and Aurora-A protein expression by immunoblot analysis, representative for 3 independent experiments.
b-Actin served as loading control.
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(c.1009C>T, p.R337C) of the tetramerization domain
(Figure 5A). This mutation was neither found in the ori-
ginal human cancer, of which this cell line was derived
from, nor in the original Kyse-410 cell line [56]. How-
ever, it was later reported in Kyse-410 cells [57]. There
are conflicting reports about whether this mutated p53
protein forms tetramers, binds DNA, induces apoptosis
and transactivates target genes or not. It seems that p53
with this mutation is partially functional depending on
the experimental conditions [58-60]. In our case, this
mutated p53 protein was clearly detectable in immuno-
blot analysis (Figure 5B) and displayed a strong nuclear
staining in most, but not all Kyse-410 cells by indirect
immunofluorescence (Figure 5C).
OE33 cells had a point mutation in exon 5 (c.404G>A,
p.C135Y), which is consistent with previous reports [57]
(Figure 5A). This mutation abolishes the p53 transacti-
vation activity as well as growth suppressive activity of
the mutated protein and has a dominant negative effect
on wild type p53 [61,62]. Accordingly, this mutated p53
protein was still expressed and accumulated in OE33
cell nuclei, although in some cells to a weaker extent
(Figure 5B, C).
OE19 cells exhibited a mutation in exon 9
(c.928_930insA, p.N310fs26X), which is in accordance
with mutation databases [57]. This mutation is within
the flexible linker, which connects the p53 core domain
with the tetramerization domain, causes a stop codon
within the tetramerization domain (protein mass of
Figure 3 Aurora-B gene copy numbers, mRNA and protein expression in normal esophageal epithelial cells and esophageal cancer
cells. A. FISH analysis of AURKB (red signals) and Chromosome 17 (CEP17; green signals). Bar = 20 μm, all panels are in the same magnification.
B. Relative Aurora-B mRNA expression was determined by qRT-PCR (mean ± standard deviation of three independent experiments). C.
Photograph of Aurora-B/phospho-T232 and Aurora-B protein expression by immunoblot analysis, representative for 3 independent experiments.
b-Actin served as laoding control.
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Page 6 of 16Table 2 Mitotic index and occurrence of multipolar mitoses in normal esophageal epithelial cells and esophageal cancer cells.
A ESCC BAC
EPC-hTERT OE21 Kyse-410 OE33 OE19
Experiment cells mitoses % cells mitoses % cells mitoses % cells mitoses % cells mitoses %
1 107 1 0.9 100 6 6.0 113 3 2.6 112 6 5.4 102 1 1.0
2 107 1 0.9 105 4 3.8 101 2 2.0 100 1 1.0 112 5 4.5
3 100 1 1.0 102 4 3.9 109 2 1.8 108 4 3.7 124 5 4.0
mitotic index (Ø) 1.0 ± 0.0% 4.6 ± 1.2% 2.2 ± 0.4% 3.4 ± 2.2% 3.2 ± 1.9%
B ESCC BAC
EPC-hTERT OE21 Kyse-410 OE33 OE19
Experiment mitoses multipolar
mitoses
% mitoses multipolar
mitoses
% mitoses multipolar
mitoses
% mitoses multipolar
mitoses
% mitoses multipolar
mitoses
%
1 81 0 0.0 100 13 13.0 101 8 7.9 104 19 18.3 101 2 2.0
2 100 1 1.0 100 7 7.0 100 7 7.0 100 10 10.0 101 1 1.0
3 84 0 0.0 100 3 3.0 100 4 4.0 100 13 13.0 100 0 0.0
multipolar mitoses
(Ø)
0.3 ± 0.6% 7.7 ± 5.0% 6.3 ± 2.0% 13.8 ± 4.2% 1.0 ± 1.0%
(A) Summary of the evaluation of the mitotic index. In three independent experiments, about 100 cells were counted and the number of mitoses therein was determined after Aurora-A immunofluorescence staining.
The table also provides mean and ± standard deviation of the percentage of mitoses. (B) Summary of the evaluation of the index of multipolar mitoses. In three independent experiments, about 100 mitoses were
counted and the number of multipolar mitoses therein was determined after Aurora-A immunofluorescence staining. The table also provides mean and ± standard deviation of the percentage of multipolar mitoses.
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6Figure 4 Occurrence of multipolar mitoses in normal esophageal epithelial cells and esophageal cancer cells.T h ef i g u r ep r o v i d e s
representative pictures of HE stainings as well as Aurora-A and pericentrin indirect immunofluorescence analyses of EPC-hTERT, OE21, Kyse-410,
OE33 and OE19 cell lines. Aurora-A staining (green) and pericentrin staining (green), each with counterstaining of DNA by DAPI (blue). Bar = 20
μm, all panels are in the same magnification. Note that the mitotic index and occurrence of multipolar mitoses were quantified according to
Aurora-A indirect immunofluorescence of three independent experiments, with multipolar mitoses (arrows) most frequently observed in OE33
and OE21 cells (see Table 2 for quantification).
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Page 8 of 16truncated protein is about 40 kDa) and most likely inac-
tivates p53 oligomerization (Figure 5A). However, the
latter is insufficient to fully abolish p53 tumor suppres-
sive function and p53 monomer mutants with retention
of transcriptional activity have been described [58]. In
OE19 cells, this potentially still functional mutated p53
protein was strongly expressed as truncated protein at
40 kDa in immunoblot analysis (Figure 5B, asterisks)
and clearly accumulated in OE19 cell nuclei (Figure 5C).
Thus, loss of function p53 mutations may result in
escape of post-mitotic G1 cell cycle control and possibly
also centrosomal dysfunction [41-45] in some (OE21,
OE33), but not all (Kyse-410, OE19) esophageal cancer
cells.
Discussion
This study addressed Aurora kinases A and B, p53
mutations and occurrence of multipolar mitoses in
aneuploid esophageal squamous cell carcinoma (ESCC)
and Barrett’s adenocarcinoma (BAC) cell lines (for data
summary refer to Table 3).
Amplification of 20q13 and/or Aurora-A has been
reported to occur frequently in human esophageal carci-
nomas by extract-based methods, such as (array-based)
comparative genomic hybridization [24,34,36,37]. The
present study confirms the importance of this chromo-
somal region in ESCC and BAC, but our precise single
cell FISH analyses of each two ESCC and BAC cell lines
suggests that high level Aurora-A gene amplification is a
Figure 5 p53 in normal esophageal epithelial cells and esophageal cancer cells. A. The p53 protein and its domain structure (modified
from [39]). The normal esophageal epithelium cell line EPC-hTERT carries no p53 mutation whereas all esophageal cancer cell lines exhibit
mutations of p53, but each in a different functional domain. Mutations are indicated by arrows (↓) and possible protein truncations by crosses
(×). B. Photograph of p53 protein expression by immunoblot analysis, representative for 3 independent experiments. Due to mutations, the p53
protein of OE21 and OE19 is truncated, resulting in protein masses of about 14 kDa and 40 kDa, respectively. For OE19 this shift in protein mass
was seen at the immunoblot (asterisks), the 14 kDa protein of OE21 cells was below the size of detectable proteins in these 10% SDS gels. b-
Actin served as laoding control. C. p53 indirect immunofluorescence (green) and DNA counterstaining by DAPI (blue). Mutated p53 accumulates
in the nucleus of Kyse-410, OE33 and OE19 cells. The truncated p53 protein of OE21 cells lacks almost all protein domains and is only weakly
expressed. Refer to text for discussion of p53 mutations.
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Page 9 of 16rather rare event in esophageal cancer cells. A clear-cut
Aurora-A gene amplification was only seen in Kyse-410
cells, as described before [24], whilst all other investi-
gated cell lines had increased Aurora-A gene copy num-
bers due to chromosome 20 polysomy. Moreover,
elevated Aurora-A gene copy numbers may not necessa-
rily result in elevated Aurora-A mRNA and/or protein
expression, as exemplified by our results of OE21 and
OE19 cells. Also, Aurora-A gene copy numbers are far
from a direct link to activated Aurora-A (phosphory-
lated at T288) protein levels. Whilst cell cycle dynamics
of esophageal cancer cells clearly impact detection levels
of Aurora-A expression, additional regulation of Aur-
ora-A expression by transcriptional, for example via epi-
dermal growth factor receptor [63], and post-
translational, for example via the ubiquitin-proteasome
pathway [64], mechanisms may further act in individual
esophageal cancer cells. Indeed, the clinical relevance of
Aurora-A in esophageal cancers has mainly been deter-
mined at the expression level [20,22,23].
In contrast to Aurora-A, there was a more close asso-
ciation between Aurora-B gene copy numbers and Aur-
ora-B mRNA and protein expression in the ESCC and
BAC cell lines. Both ESCC cell lines (OE21, Kyse-410)
had elevated Aurora-B gene copy numbers due to chro-
mosome 17 polysomy and concomitant high Aurora-B
expression, but not activation (phosphorylation at
T232). Instead, both BAC cell lines (OE33, OE19) dis-
played lower Aurora-B gene specific signals than chro-
mosome 17 specific signals with concomitantly low
Aurora-B mRNA as well as protein expression and
activity. In fact, also our previous studies showed broad
chromosomal deletions on 17p close to the Aurora-B
locus in up to 40% of tissue specimens of BACs [36,37],
whilst other investigators reported controversial results
for chromosome 17p alterations in tissue specimens of
ESCC [34,35]. In order to rule out that this is due to a
major chromosome 17 alteration, we performed FISH
and immunoblot analysis for HER2 (17q21), clearly
demonstrating that HER2 is highly amplified in these
two BAC cell lines. This suggests that the detected
genomic alteration is specific to 17p, respective poten-
tially the Aurora-B gene. The apparently “reduced” Aur-
ora-B gene copy numbers in BAC cells may be due to a
partial deletion, loss of the short arm of chromosome 17
or even duplication of centromere 17 alone. It will be of
interest for future studies to investigate potentially
deregulated chromosome integrity, for example by telo-
mere alterations or breakage-fusion-bridge cycles, during
mitosis of BAC cells.
Irrespective of this, the present results allow further
insights into the direct association of high Aurora-A
Table 3 Summary of investigated parameters in normal esophageal epithelial cells and esophageal cancer cell lines.
ESCC BAC
EPC-hTERT OE21 Kyse-410 OE33 OE19
Aurora-A
Aurora A gene copies 2.0 ± 0.2 4.2 ± 0.5 9.1 ± 1.2 7.5 ± 0.9 3.9 ± 0.3
Centromere 20 signals 1.9 ± 0.3 4.1 ± 0.7 4.6 ± 0.9 7.2 ± 0.9 2.9 ± 0.4
Aurora-A mRNA 0.4 ± 0.1 0.8 ± 0.1 2.7 ± 0.3 1.3 ± 0.3 1.6 ± 0.1
Aurora-A protein ++ + +++ +++ +
Aurora-A/phospho T288 + + + (+) (+)
Aurora-B
Aurora-B gene copies 1.9 ± 0.4 3.0 ± 0.1 3.6 ± 0.8 2.9 ± 0.7 2.0 ± 0.2
Centromere 17 signals 2.0 ± 0.2 3.0 ± 0.1 3.8 ± 0.7 4.9 ± 0.7 3.9 ± 0.4
Aurora A mRNA 0.7 ± 0.0 1.2 ± 0.3 1.5 ± 0.5 0.7 ± 0.4 0.8 ± 0.2
Aurora-B protein (+) +++ ++++ ++ +
Aurora-B/phospho T232 (+) + + + -
p53
Mutations no mutation c.269C>T, c.270delC, p.S90fs31X c.1009C>T, p.R337C c.404G>A, p.C135Y c.928_930insA, p.N310fs26X
p53 protein (kDa) 53 ~14 (truncated) 53 53 ~40 (truncated)
p53 functionality + - +/- + +/-
Mitoses
Mitotic Index (%) 1.0 ± 0.0% 4.6 ± 1.2% 2.2 ± 0.4% 3.4 ± 2.2% 3.2 ± 1.9%
Multipolar mitoses (%) 0.3 ± 0.6% 7.7 ± 5.0% 6.3 ± 2.0% 13.8 ± 4.2% 1.0 ± 1.0%
Quantitative data of each three independent experiments are summarized for FISH and q-RT-PCR (relative mRNA expression) analyses as well as for mitoses and
multipolar mitoses (mean and ± standard deviation). Immunoblot analyses are depicted with minus (-) to increasingly positive (+ to ++++) protein expression.
Identified p53 mutations and associated effects are listed.
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associated occurrence of multipolar mitoses and aneu-
ploidy described in other model systems [27,30] now
also for aneuploid esophageal cancer cells. For example,
ectopic overexpression of functional Aurora-A in diploid
colorectal cancer cell line [31] or ectopic expression of
kinase deficient Aurora-A isoforms, which is unable to
phosphorylate its substrate Lats2, in immortalized fibro-
blasts [32] both resulted in either supernumerary cen-
trosomes, chromosome segregation defects and/or
genomic instability.
In fact, we found that high Aurora-A expression in
aneuploid ESCC or BAC cells does not determine the
occurrence of multipolar mitoses alone: 1) although
exhibiting similarly high Aurora-A expression, only
OE33 cells, but not Kyse-410 cells were characterized by
a high frequency of multipolar mitoses and 2) of the
two cell lines with markedly lower Aurora-A expression
(OE21, OE19), OE21 cells did in fact show a noticeable
frequency of multipolar mitoses, being higher than in
strongly Aurora-A expressing Kyse-410 cells.
Thus, other factors are required to sustain cycling of
multipolar mitotic esophageal cancer cells in order to
allow development and maintenance of individual aneu-
ploid ESCC and BAC cell clones. Since up to 80% of
ESCC and 90% of BAC display mutations of p53
[4,10,11], this tumor suppressor protein is a very likely
contributing factor, particularly in view of its role in G1
cell cycle and DNA damage control, its centrosomal
function [39-43] as well as its inactivation and/or degra-
dation upon interaction with Aurora-A [44,45]. Thus,
cells with still intact or only partial dysfunctional p53
protein may still have p53 dependent G1 cell cycle con-
trol, a scenario that was of interest for the present data,
particularly for the ESCC Kyse-410 cells.
In the present study, p53 mutations were found in the
four representative esophageal cancer cell lines, but in
different domains and therefore with different conse-
quences for protein expression and/or function. None of
the p53 mutations detected corresponded to known p53
gain of function mutations [65]. Instead, OE21 cells had
p53 mutations (exon 4; c.269C>T, c.270delC, p.
S90fs31X), which caused weak expression of a presum-
ably non-functional, largely truncated (about 14 kDa)
p53 protein. Also OE33 cells had a p53 mutation (exon
5; c.404G>A, p.C135Y) resulting in a non-functional,
nuclear accumulated p53 protein, lacking transactivation
and growth suppressive activity [61,62]. In contrast,
Kyse-410 cells had a cell culture acquired [56,57] p53
mutation (exon 10; c.1009C>T, p.R337C), resulting in
expression and nuclear accumulation of an at least par-
tially functional p53 protein [58-60]. Similarly, the p53
mutation confirmed in OE19 cells (exon 9;
c.928_930insA, p.N310fs26X) [57], may cause expression
of a truncated (about 40 kDa), but still partially func-
tional p53 protein with lost oligomerization activity [58].
Thus, esophageal cancer cells with both high Aurora-A
expression and p53 loss of function mutations have a
high occurrence of multipolar mitoses (e.g. OE33: about
14% multipolar mitoses). In contrast, esophageal cancer
cells with Aurora-A gene amplification and high Aur-
ora-A expression, but an at least partially functional p53
protein have fewer multipolar mitoses (e.g. Kyse-410:
about 8% multipolar mitoses).
In contrast to the esophageal cancer cells, the normal
esophageal epithelial cell line EPC-hTERT [50,51] was
diploid, had wild type p53 and did show normal Aur-
ora-A and Aurora-B gene copy numbers as well as bipo-
lar mitoses. Still, slightly elevated Aurora-A and p53
protein levels were observed in this cell line. Although
no effect of hTERT was seen on p16 and p53 protein
levels in the initial description of this cell line [51],
others have reported an effect of hTERT-induced down-
regulation of p16, p21 and up-regulation of Aurora-A in
normal esophageal epithelial cells [66], which may
explain the detectable Aurora-A protein expression
observed in our experiments of EPC-hTERT cells.
Conclusions
In summary, high Aurora-A expression together with
p53 mutations may contribute to aneuploid esophageal
cancer cells via supernumerary centrosomes and asso-
ciated occurrence of multipolar mitoses. This is hetero-
geneous in single ESCC or BAC cell lines, thereby
reflecting the heterogeneity also observed in individual
patients with ESCC or BAC [20-25]. The study therefore
represents a basis for further translational assessment of
Aurora kinases and associated cell cycle control in aneu-
ploid ESCC and BAC cells, particularly also in view of
discussions of Aurora kinases as therapeutic targets
[17,67,68]. Further assessment of Aurora kinases and
p53 interactions in cell lines or tissue specimens derived
from precursor lesions of dysplasia (for ESCC) or intest-
inal metaplasia (for BAC) are necessary to disclose a
causative role of Aurora kinases and p53 in the develop-
ment of aneuploid, invasive esophageal cancers.
Methods
Cell culture
The study included as control a normal esophageal
epithelial cell line (EPC-hTERT cells) [50,51] as well as
four esophageal cancer cell lines (OE21, Kyse-410,
OE33, OE19). The esophageal cancer cell lines were ori-
ginally derived from patients with esophageal squamous
cell carcinomas (ESCC: OE21, Kyse-410), Barrett’sa d e -
nocarcinoma (BAC: OE33) or an esophageal junctional
adenocarcinoma (OE19) [47,48]. Indeed, the specificity
of the adenocarcinoma cell lines was recently approved
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growth patterns, the two cell lines OE33, OE19 are col-
lectively referred to as “BAC” in the present in vitro
study, which does not address the carcinogenesis of eso-
phageal carcinomas in view of the intestinal metaplasia-
dysplasia-carcinoma sequence.
EPC-hTERT cells were cultivated in Keratinocyte-SFM
medium (Invitrogen, Karlsruhe, Germany) supplemented
with 40 μg/ml bovine pituitary extract (Invitrogen,
Karlsruhe, Germany), 1.0 ng/ml EGF (Invitrogen, Karls-
ruhe, Germany), 100 units/ml penicillin and 100 μg/ml
streptomycin (Invitrogen, Karlsruhe, Germany) at 37°C
in a 5% CO2 atmosphere.
The esophageal cancer cell lines OE21 and Kyse-410
and the BAC cell lines OE33 and OE19 (European Col-
lection of Cell Cultures, Salisbury, UK) were cultivated
in RPMI 1640 medium (PAA Laboratories, Pasching,
Austria), supplemented with 10% (v/v) Fetal Bovine
Serum (PAA Laboratories, Pasching, Austria) and 2 mM
GIBCO™ L-Glutamin (Invitrogen, Karlsruhe, Germany)
at 37°C in a 5% CO2 atmosphere.
Hematoxylin and Eosin staining (HE staining)
Cells grown on coverslips were fixed with 4% parafor-
maldehyde (PFA), rinsed with Phosphate buffered saline
(PBS: 137 mM NaCl, 10 mM Na2HPO4,1 . 8m M
KH2PO4; pH 6.8-7) and stained with Hematoxylin (Carl
Roth, Karlsruhe, Germany). After removing the hema-
toxylin solution mains water was added twice. Cells
were stained with Eosin Y solution (Carl Roth, Karls-
ruhe, Germany) and distilled water was added. The cov-
erslips were then immersed in an ascending ethanol
series and in xylol.
Cell cycle phase distribution analysis by flow cytometry
For cell cycle distribution analyses by flow cytometry
cells were grown to 50%-60% confluency. The cells in
the medium and trypsinized cells were collected and
fixed in ice-cold 70% (v/v) ethanol. After washing with
PBS cells were stained with propidium iodide (20 μg/ml
propidium iodide (Sigma-Aldrich, Steinheim, Germany),
0.1% (v/v) Tritron X-100, 0.2 mg/ml Ribonuclease A
(Sigma-Aldrich, Steinheim, Germany) in PBS). Stained
cells were analyzed using the LSRII system and DB
FACS Diva software (Becton Dickinson, Heidelberg,
Germany).
Fluorescence in situ hybridization (FISH)
Cells were grown on Poly-L-Lysine coated Lab-Tek
® 1
Well Glass Slides (Thermo Fisher Scientific, Langensel-
bold, Germany). Cells were washed with PBS, fixed in
3:1 methanol/glacial acetic acid and dehydrated in an
ethanol series. AURKA (20q13) & 20q11 DNA probe
(Kreatech Diagnostics, Amsterdam, Netherlands) or
AURKB (17p13)/Alphasatellite 17 specific DNA probe
(MP Biomedicals, Illkirch, France) was applied. Co-dena-
turation was performed for 5 min at 75°C for AURKA or
80°C for AURKB probes and hybridization for 16-18 h
at 37°C in a humidified chamber. After washing in 0.4×
SSC/0.3% (v/v) NP-40 pH 7 for 2 min at 73°C and in 2×
SSC/0.1% (v/v) NP-40 pH 7-7.5 for 1 min at room tem-
perature (RT), cell nuclei were counterstained with
DAPI (Vector Laboratories, Burlingame, USA). Examina-
tion was done at a fluorescence microscope (Axioplan2
imaging microscope equipped with a Plan-Apochromat
63×/1.4 oil objective, Carl Zeiss MicroImaging, Göttin-
gen, Germany) with slider module. Image stacks at 0.9
μmi n t e r v a l sw e r et a k e no fa tl e a s tt h r e er e p r e s e n t a t i v e
fields per cell line. Image stacks were converted into 3D
view by AxioVision software (Carl Zeiss MicroImaging,
Göttingen, Germany).
For each cell line, the gene (AURKA or AURKB)a n d
chromosome specific signals (centromer enumeration
probes/CEP; CEP20 or CEP17) were counted per indivi-
dual cell nucleus (range of cell nuclei counted: 49-88; a
mean of 71.3 ± 13.1 cell nuclei per cell line). The mean
and standard deviation of the gene (AURKA or AURKB)
and chromosome specific signals (CEP20 or CEP17) of
counted cell nuclei were calculated for each cell line.
The FISH ratio (AURKA to CEP20 and AURKB to
CEP17) was calculated for each analyzed cell nucleus
and thereof the mean and standard deviation was calcu-
lated for each cell line. True gene-specific amplification
w a sc o n s i d e r e da taF I S Hr a t i oo f> 2 .T h eF I S Hp r o c e -
dure and quantification has previously been published
by us for evaluation of Aurora-A and other gene copy
numbers in tissue specimens [18].
Indirect immunofluorescence and evaluation of mitoses
Cells were grown on coverslips, fixed in 2% PFA,
washed in PBS and permeabilized in 0.5% (v/v) Tritron
X-100 in PBS. After PBS washing, cells were incubated
with blocking buffer (PBS containing 5.0% (v/v) normal
goat serum and 0.3% (v/v) Tritron X-100). Diluted pri-
mary antibodies (mouse anti-IAK1/Aurora-A Kinase,
1:100, clone 4, BD Biosciences, Heidelberg, Germany;
mouse anti-pericentrin, 1:1000, clone mAbcam 28144,
Abcam, Cambridge, UK; mouse anti-p53, 1:50, clone
DO-7, DakoCytomation, Hamburg, Germany) were
incubated over night at 4°C, cells were rinsed with PBS
and 1:200 diluted fluorescently labelled secondary anti-
bodies (goat-anti-mouse IgG-Alexa488, Invitrogen,
Karlsruhe, Germany), were incubated for 1 h at RT.
After washing with PBS and distilled water, cell nuclei
were counterstained with DAPI (Vector Laboratories,
Burlingame, USA). Note that the p53 antibody used was
raised against the N-terminal domain (amino acids 1-
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cated) p53 proteins.
Normal bipolar mitoses were defined as mitotic cells
with 2 Aurora-A positive centrosomes/spindle poles.
Multipolar mitoses were defined as mitotic cells with >2
Aurora-A positive centrosomes/spindle poles. In three
independent experiments, cells were screened using a
x40 objective and a minimum of 100 cells were counted
for the mitotic index (mitoses per cells counted in %;
range of total cells counted: 100-124) and up to 100
mitoses per cell line were evaluated for the occurrence
of multipolar mitoses (multipolar mitoses per mitoses
counted; range of total mitoses counted: 81-104) (Table
2).
Immunoblotting
Preparation of total protein and determination of pro-
tein concentration was performed using the Qpro-
teome™ Mammalian Protein Prep Kit (Qiagen, Hilden,
Germany) and the DC Protein Assay (Bio-Rad,
München, Germany) according to the manufacturer’s
protocols. 10 μg of total protein extracts per lane were
loaded onto 10% polyacrylamide gels. Proteins were
transferred onto Protran
® Nitrocellulose Transfer Mem-
brane (Whatman, Dassel, Germany) by Semi-Dry Blot.
After blocking the membrane in 5% (m/v) nonfat dried
milk powder in Tris buffered saline with Tween (TBST:
10 mM Tris-Base, 150 mM NaCl, 0.1% (m/v) Tween;
pH 7.2-7.4), the primary antibodies diluted in 5% (m/v)
nonfat dried milk powder inT B S T( m o u s ea n t i - I A K 1 /
Aurora-A Kinase, 1:250, clone 4, BD Biosciences, Hei-
delberg, Germany; rabbit anti-Aurora-B, 1:5000, clone
EP1009Y. Epitomics, Burlingame CA, USA; mouse anti-
p53, 1:1000, clone DO-7, DakoCytomation, Hamburg,
Germany; mouse anti-b-Actin, 1:1000, clone AC-15,
Sigma-Aldrich, Steinheim, Germany) or 3% BSA in
TBST (rabbit anti Aurora-A/phospho-T288, 1:1000,
clone C39D8, Cell signalling, Danvers MA, USA) or 5%
BSA in TBST (rabbit anti-Aurora-B/phospho-T232,
1:500, Abcam, Cambridge, UK) were incubated. After
HRP conjugated secondary antibody (1:25000, Dianova,
Hamburg, Germany) incubation, the membrane was
incubated with ECL reagents (GE Healthcare, Freiburg i.
Br., Germany) and exposed to autoradiography films.
Note that the p53 antibody used was raised against the
N-terminal domain (amino acids 1-45), recognizing also
mutated and expressed (also truncated) p53 proteins.
p53 mutation analysis
Genomic DNA was isolated using the QIAamp
® DNA
Micro Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instruction. Amplification of p53 exons
2-11 was performed using primers and protocols slightly
modified from previous studies [54,55]. PCR was carried
out in a 25 μl reaction mixture containing 1× PCR Buf-
fer, 1.5-2.5 mM MgCl2, 12 ng/μlg D N A ,0 . 4m Md N T P
Mix, 0.4 μM forward and reverse primers and 1.25 U
Taq DNA polymerase. The PCR was performed with
the following conditions: 94°C for 4 min, 40 cycles con-
sisting of 94°C for 30 sec, 53-65°C for 30 sec and 72°C
for 30 sec, followed by 72°C for 7 min. PCR products
were purified using the QIAquick
® PCR Purification Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. Sequencing was performed using Big-
Dye
® Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, Darmstadt, Germany) according to the man-
ufacturer’s instruction. The reactions were performed in
20 μl reaction mixture consisting of 3-5 ng PCR pro-
duct, 0.16 μM forward or reverse primers, 20% (v/v)
BigDye
® Ready Reaction Mix and 1× Big Dye
® Sequen-
cing Buffer. A positive control with a 20 μl reaction
mixture containing 5% (v/v) pGEM
®-3Zf(+) double-
stranded DNA control Template, 5% (v/v) -21 M13
Control Primer (forward), 20% (v/v) BigDye
® Ready
Reaction Mix and 1× Big Dye
® Sequencing Buffer was
included. The PCR was performed with the following
conditions: 96°C for 1 min, 24 cycles consisting of 96°C
for 10 sec, 50°C for 5 sec and 60°C for 4 min. DNA was
precipitated with ethanol containing 5 mM EDTA and
120 mM sodium acetate, dissolved in formamide and
denatured for 5 min at 95°C. Capillary electrophoresis
was performed using the ABI PRISM™ 310 Genetic
Analyzer (Applied Biosystems, Darmstadt, Germany).
The Sequencing Analysis Software V 5.2 (Applied Bio-
systems, Darmstadt, Germany) was used to analyze the
collected electropherogram traces and sequencing infor-
mation. The p53 sequence of the GenBank database
with accession number NC_000017.9|NC_000017:
c7531642-7512445 was used as reference.
RNA isolation and cDNA synthesis
Total RNA isolation was performed using the RNeasy
®
Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instruction. For cDNA synthesis, a 9 μl
reaction mixture containing 200 ng total RNA, 1 μl
yeast RNA (10 ng/μl) and 2 μl Hexanucleotide Mix
(10×, Roche Diagnostics, Mannheim, Germany) was
incubated for 2 min at 70°C and 10 min at RT. A sec-
ond 11 μl reaction mixture containing 4 μlF i r s tS t r a n d
Buffer (5×, Invitrogen, Karlsruhe, Germany), 2 μlD T T
(0.1 M), 1 μld N T PM i x( 1 0m M )a n d1μlM - M L VR T
(200U/μl, Invitrogen, Karlsruhe, Germany), was added
and incubated for 1 h at 37°C. The M-MLV RT was
inactivated for 5 min at 95°C. For reverse transcription
of Universal Human Reference RNA (uRNA) (Strata-
gene, Heidelberg, Germany) [69], the calibrator of qRT-
P C R ,3 0 0n gR N Aw a se m p l o y e di na na p p r o p r i a t e
volume.
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qRT-PCR was performed using established protocols for
Aurora-A and TBP [18]. Following Aurora-B primers
and probes were used (sequence 5’-3’): Aurora-B-for-
ward (900 nM): CAT GAG CCG CTC CAA TGT C,
Aurora-B-reverse (50 nM): CCC AAT CTC AAA GTC
ATC AAT TGT, Aurora-B-probe (150 nM): 6-FAM-
ACA CCC GAC ATC TTA ACG CGG CA-TAMRA.
The comparative Ct method was used to calculate Aur-
ora-A/-B mRNA levels. The amount of the target gene
is normalized to the endogenous housekeeping gene
TATA box binding protein (TBP) and these relative fold
differences are compared between the experimental and
the uRNA calibrator sample [69,70].
Additional material
Additional file 1: Supplementary Figure S1: HER2 gene copy
numbers in esophageal cancer cells. FISH analysis of HER2 (red signals)
and Chromosome 17 (CEP17; green signals). All panels are in the same
magnification. Note HER2 gene amplification in OE33 and OE19 cells and
chromosome 17 polysomy in all cell lines.
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